A multigene test could cost-effectively help extend life expectancy for women at risk of hereditary breast cancer. Value Health. 2017;20(4):547-555. doi:10.1016/j.jval.2017.01.006Crossref 60. Havrilesky LJ, Broadwater G, Davis DM, et al. Determination of quality of life-...
法国居里癌症研究所于2021年9月在《npj Breast Cancer》杂志发表多中心前瞻性研究"COMET"相关结果,研究评估了转移性乳腺癌患者基线和化疗后循环肿瘤细胞(CTC)及循环肿瘤DNA(ctDNA)水平,认为CTC和ctDNA具有互不重叠、互相补充的临床价值,CTC联合ctDNA检测可以得到更加精确的预后信息,有助于患者生存预测和一线治疗策略的...
Cost Minimization Relies on Sequencing in Metastatic Breast Cancer Investigators Seek to Resolve the “Obesity Paradox” in Lung Cancer Novel Interventions May Reduce Phlebotomy Use in Patients With Polycythemia Vera Novel AR-Targeted Therapies for Metastatic Hormone-Sensitive Prostate Cancer: Which One to...
The stage of the cancer, or where it is and how big it is The grade of the cancer, which is how fast it’s growing Other details about the cancer cells, such as the amount of DNA changes in them, whether they have hormone receptors, and gene expression test results Your age and ove...
Every woman successfully treated for breast cancer lives with the knowledge that it could come back. New research published today in the journal Clinical Epigenetics may lead to a simple blood test to determine the risk of such recurrence, or the cancer
Breast cancer is the most prevalent kind of cancer among women and there is a need for a reliable algorithm to predict its prognosis. Previous studies focused on using gene expression data to build predictive models. However, recent advancements have made multi-omics cancer data sets (gene expres...
Dr Sardesai on Lasofoxifene Plus Abemaciclib in ESR1-Mutant, ER+/HER2– Breast Cancer Effects of trastuzumab deruxtecan (T-DXd) on health-related quality of life (HRQOL): DESTINY-Breast12 (DB-12) results Dr Grinshpun on Ultra-Sensitive ctDNA Detection in HR+ Early Breast Cancer ...
between NGS and recent molecular prognostic tests, taking into account evidence-based clinical and biological significance, cost-effectiveness, practicality of application in different parts of the world, and the impact of this on future plans for improvement in breast cancer prognostication and ...
Testing for germline BRCA1/2 mutations has an established predictive role in breast cancer risk assessment. More recently, studies have also identified BRCA1/2 status as clinically relevant in the selection of therapy for patients already diagnosed with
Circulating tumour DNA (ctDNA) allows tracking of the evolution of human cancers at high resolution, overcoming many limitations of tissue biopsies. However, exploiting ctDNA to determine how a patient’s cancer is evolving in order to aid clinical decisions remains difficult. This is because ctDN...